IQVIA HOLDINGS INC. (IQV): what the price requires

At today's price, IQVIA HOLDINGS INC. (IQV) is priced for +15.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/IQV

Headline

FieldValue
TickerIQV
CompanyIQVIA HOLDINGS INC.
Current price$207.75/sh
CompositionTechnology & Analytics Solutions 41% / Research & Development Solutions 55% / Contract Sales & Medical Solutions 5%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed7.4%
Operating margin today12.9%
Margin compression implied-5.5pp
Implied growth15.8%
Multiple paid23x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.5% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.5pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.35σ
cohort percentile (of 112 peers)59
sustained it ~5 years at this level43%
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.36x5expensive
Earnings3.66x5expensive
Relative0.74x5justifies
Growth0.85x3justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.7%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$439.720.47xyesFCF base $2.2B, growth 7% (input: historical growth), terminal g 4.0%, WACC 6.7%, 5yr projection
DCF Exit MultipleGrowth$243.960.85xyesExit EV/EBITDA: 12.7x / 14.7x / 16.7x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$279.220.74xyesP/E 28x (static sector reference · 2026-04), scenarios: 23.5x / 28.0x / 32.5x (bear / base = reference held flat / bull), EV/EBITDA 20x
Simple DDMGrowthno
Two-Stage DDMGrowthno
Simple Excess ReturnAsset$88.182.36xyesBV/sh $36.64, ROE (TTM) 22.3%, ke 9.3%
Two-Stage Excess ReturnAsset$136.151.53xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$167.051.24xyesRev $16.6B, growth 7% (input: historical growth; tapered), Terminal P/S: 1.8x / 2.1x / 2.5x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$96.602.15xyesEPS $8.05, growth 10% (input: historical EPS growth), PEG=2.49 (Overvalued)
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$56.813.66xyesNormalized EBIT (5y avg op income, one-time charges added back) $2.01B × (1−21%) / WACC 6.7% → EPV (no growth)
Residual IncomeAsset$127.291.63xyesBV $36.64 + 5yr PV of (ROE (TTM) 22.3% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$81.462.55xyes√(22.5 × EPS $8.05 × BVPS $36.64) — Graham's conservative floor
EV/EBITDA RelativeRelative$313.440.66xyesEBITDA $3.37B × sector EV/EBITDA 20.0x
FCF YieldEarnings$51.584.03xyesFCF $2116.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$36.305.72xyesSBC-adj FCF $1.88B (FCF $2.12B − SBC $0.24B) capitalized at Kₑ
Ben Graham FormulaEarnings$195.401.06xyesEPS $8.05 × (8.5 + 2×10.2%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$11.0018.89xyesBV $36.64 × (ROIC 2.0% / WACC 6.7%)
P/Sales SectorRelative$587.700.35xyesRevenue $16.63B × sector P/S 6.0x
PEG Fair ValueRelative$123.541.68xyesEPS $8.05 × (PEG 1.5 × growth 10.2% (input: historical EPS growth)) → PE 15.3x
Earnings YieldEarnings$87.032.39xyesEPS $8.05 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$13.9b
Net debt / NOPAT (after-tax)8.53x
Net debt / operating income (pre-tax)6.74x
Interest coverage2.8x
Share count CAGR (buyback)-3.2%
Burning cashno

Bullet Takeaways

Bull Case

The clearest window into IQVIA is its capital allocation, because it shows what management believes its own stock is worth and how the business converts revenue into shareholder value. Even while carrying significant debt, the company has been reducing its share count, down about 3% a year, which means it is buying back stock rather than diluting, deploying cash flow into its own equity. That is a deliberate signal: management is choosing per-share value over empire-building, funded by the steady cash a services-and-data business throws off.

The business underneath is a genuine two-sided moat. On one side, IQVIA is one of the largest contract research organizations, running the clinical trials that drug companies increasingly outsource rather than staff internally. On the other, it owns one of the deepest commercial datasets in healthcare, the prescription, sales, and patient-level information pharma relies on to target and measure its products. The two reinforce each other: trial relationships generate data, and data insight wins trial work. The most recent quarter showed both engines running, with Commercial Solutions up 11.6% and R&D Solutions up 6.2%, and R&D net new bookings rising to $2.5 billion from $2.2 billion a year earlier at a book-to-bill above 1. Bookings outpacing revenue is the leading indicator of future growth, and the backlog converts roughly $8.9 billion to revenue over the next year.

The outsourcing tailwind is the durable part of the thesis. Drug companies face pressure to develop more therapies with leaner internal teams, and the 10-K points to "outsourcing trends in the biopharmaceutical industry" as a driver of demand for IQVIA's services. As pharma pushes more of its R&D and commercial work to specialized partners, the largest, most data-rich partner captures a disproportionate share. The company raised full-year EPS guidance on the strong quarter, and the stock rallied on the print, reflecting confidence that the bookings momentum carries forward.

Bear Case

The moat-erosion risk worth taking seriously is that IQVIA's data advantage, the thing that has set it apart, is being chipped at from two directions. The 10-K itself warns of "increased competition from firms that may have lower costs to market (e.g., no data supply costs)", competitors who can undercut IQVIA precisely because they do not carry the expense of assembling and licensing the data IQVIA is proud of. As more healthcare data becomes available and AI lowers the cost of analyzing it, the premium IQVIA charges for its proprietary insight faces pressure. The asset that justifies the premium multiple is exactly the one technology and new entrants are working to commoditize.

The demand side is outside the company's control and currently under strain. IQVIA's revenue depends on how much the drug industry spends on clinical trials and commercial analytics, and biopharma clients are facing budget pressure. Smaller and mid-sized biotechs, a meaningful source of trial work, are sensitive to the funding environment, and when biotech funding tightens, trial starts slow and bookings can soften. The 10-K also names a structural conflict: relationships with clients "who are in competition with each other may adversely impact the degree to which other clients" use IQVIA's services. Being everyone's partner in a competitive industry has limits.

The balance sheet is where the bear bites hardest if demand wavers. IQVIA carries net debt of roughly $14 billion, more than six times trailing operating income, with interest coverage around 3 times. The price is reached only by the relative-multiple and forward-growth methods; the asset-based and earnings-power lenses say it is expensive. So a buyer is paying a growth-supported multiple for a levered company whose growth depends on a client base under budget pressure. If bookings decelerate or biopharma spending contracts, the leverage that is manageable in good times becomes the amplifier on the downside. The business is excellent and currently executing well, but the price assumes that execution and the spending environment both continue.

Valuation

IQVIA is priced as a quality compounder in healthcare services, and the price embeds an assumption of high-single-digit forward growth carried by the backlog and the outsourcing tailwind. The inversion implies roughly 9% growth, which is close to the 8.4% revenue growth the company just printed, so the assumption is grounded in current results rather than a stretch.

The methods split along the usual line for an asset-light services franchise. The relative-multiple and forward-growth families reach the price; the asset-based and earnings-power lenses sit below it and call the stock expensive. For a business whose value is its data, its client relationships, and its $8.9 billion of convertible backlog rather than its physical assets, that pattern is expected. The premium is the durability premium on the outsourcing-and-data moat, and it holds as long as bookings keep outpacing revenue, which they did this quarter at a book-to-bill above 1. Among the contract-research and life-science-services peers, IQVIA is valued on the strength of its backlog and data assets rather than on a re-rating thesis.

Solvency is the constraint that keeps the bull honest. IQVIA carries net debt of roughly $14 billion, more than six times trailing operating income, with interest coverage around 3 times. That leverage is serviceable while the business grows and generates cash, and the company has used that cash to buy back stock, shrinking the share count about 3% a year. But it is the amplifier on the downside: if biopharma spending contracts or bookings decelerate, the debt that is comfortable in a strong market becomes the pressure point. The decisive variable is the trajectory of client R&D budgets, because that determines whether the backlog keeps refilling at the pace the price assumes.

Catalysts

The most recent quarter, the first of 2026, beat expectations and prompted a guidance raise. Revenue rose 8.4% year over year to $4.151 billion, ahead of consensus, with adjusted diluted EPS of $2.90 up 7.4%, and the stock rallied roughly 9% on the print. Commercial Solutions grew 11.6% and R&D Solutions 6.2%, while adjusted EBITDA reached $932 million.

The forward-looking signal was the bookings. R&D net new bookings climbed to $2.5 billion from $2.2 billion a year earlier, a book-to-bill of 1.04, and the backlog set up roughly $8.9 billion of conversion to revenue over the next twelve months. IQVIA reaffirmed full-year revenue and adjusted EBITDA guidance while raising its full-year adjusted EPS range to $12.65 to $12.95.

The forward watch items center on the biopharma spending environment. Management framed the results as resilience even as clients face budget pressure and lean on AI-driven efficiencies. Because the company's growth depends on how much the drug industry spends on trials and analytics, the pace of net new bookings each quarter, and any shift in biotech funding, are the catalysts that confirm or challenge the backlog-driven outlook.

Peer Cohorts (Per Segment, With Filing Citations)

Technology & Analytics Solutions (reported)

Research & Development Solutions / Contract Sales & Medical Solutions (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

IQVIA Q1 2026 earnings release

View the full interactive IQV report on boothcheck